Evidence digest
What the research on Melanotan I actually shows
The indexed literature on Melanotan I includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Melanotan I is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
Updated 25 Aug 2026 · 4 studies indexed · 4 human · compound record
- Studies indexed
- 4
- Human evidence
- 4
- Preclinical only
- 0
What is and is not established
What the literature supports
- Human clinical or observational records are indexed for Melanotan I (4).
- Published research is indexed back to 1980, with roughly 345 PubMed records located.
- It is listed by one or more vendors tracked in this index.
What is NOT established
- This index does not evaluate whether Melanotan I is safe or effective for any use.
- Material sold by the vendors indexed here is labeled for laboratory research use only and is not a regulator-approved medicine in that form.
- No dosing, protocol or human-use guidance is provided or implied anywhere in this index.
Studies indexed
2 human — controlled trial · 1 human — observational · 1 systematic review
| Study | Evidence type | Model | n | What it reported | Source |
|---|---|---|---|---|---|
| Afamelanotide for Erythropoietic ProtoporphyriaThe New England journal of medicine · 2015 | Human — controlled trial | Not recorded | — | Erythropoietic protoporphyria is a severe photodermatosis that is associated with acute phototoxicity. Patients with this condition have excruciating pain and a markedly reduced quality of life. We evaluated the safety and efficacy of an α-melanocyte-stimulating hormone analogue, afamelanotide, to decrease pain and improve quality of life. We conducted two multicenter, randomized, double-blind, placebo-controlled trials of subcutaneous implants containing 16 mg of afame… | PMID 26132941 |
| Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyriaThe British journal of dermatology · 2015 | Human — observational | Not recorded | — | In erythropoietic protoporphyria (EPP), an inherited disease of porphyrin-biosynthesis, the accumulation of protoporphyrin in the skin causes severely painful phototoxic reactions. Symptom prevention was impossible until recently when afamelanotide became available. Afamelanotide-induced skin pigmentation has statistically significantly improved light-tolerance, although the clinical significance of the statistical effect was unknown. To assess clinical effectiveness by recor… | PMID 25494545 |
| Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trialJAMA dermatology · 2015 | Human — controlled trial | Not recorded | — | Narrowband UV-B (NB-UV-B) phototherapy is used extensively to treat vitiligo. Afamelanotide, an analogue of α-melanocyte-stimulating hormone, is known to induce tanning of the skin. To evaluate the efficacy and safety of combination therapy for generalized vitiligo consisting of afamelanotide implant and NB-UV-B phototherapy. This study was performed in 2 academic outpatient dermatology centers and 1 private dermatology practice. We enrolled men and women 18 years or ol… | PMID 25230094 |
| A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligoSkin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] In · 2024 | Systematic review | Not recorded | — | The purpose of this study is to investigate the effectiveness and safety of oral and injectable systemic treatments, such as methotrexate, azathioprine, cyclosporine, tofacitinib, baricitinib, corticosteroids, statins, zinc, apremilast, etc., for treating vitiligo lesions. Databases including PubMed, Scopus, and Web of Science were meticulously searched for studies spanning from 2010 to August 2023, focusing on systemic oral and injectable therapies for vitiligo, using compre… | PMID 38454597 |
Vendors listing Melanotan I
The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.
| Vendor | Score · Coverage | Certificates | |
|---|---|---|---|
| Ascend Science | 90.291% | 1 | profile → |
| PeptidePlugs | 89.790% | 2 | profile → |
| American Peptides | 83.6100% | 1 | profile → |
| Origin Labs | 81.885% | 1 | profile → |
| Northline Labs | 79.493% | 1 | profile → |
| NeuroLabs Research | 79.386% | 2 | profile → |
| ZC Labs | 79.384% | 1 | profile → |
| Good Science Bio | 79.275% | 0 | profile → |
| Ascension Peptides | 78.186% | 1 | profile → |
| Simple Peptide | 7489% | 1 | profile → |
| Improved Peptides | 7089% | 1 | profile → |
| Eternal Peptides | 68.265% | 0 | profile → |
| BioLongevity Labs | 67.274% | 0 | profile → |
How to read this page
This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.